Pfizer Inc. (NYSE: PFE), Astellas Pharma Inc. today announced that the Phase 3 ARCHES trial evaluating XTANDI® (enzalutamide) plus androgen ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Hot FDA News Management Comments

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate CancerDecember 20, 2018 9:00 AM Pre-Open Stock Movers 12/19: (ADRO) (CIVI) (JBL) Higher; (SURF) (GSAT) (MU) (FDX) Lower (more...)December 19, 2018 9:27 AM GlaxoSmithKline (GSK) Pfizer (PFE) Joint Venture Details - Morgan StanleyDecember 19, 2018 8:51 AM Pfizer (PFE), GlaxoSmithKline (GSK) Enter Joint Venture Agreement to Create Premier Global Consumer Healthcare CompanyDecember 19, 2018 6:01 AM